Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Quidel Rallies On Earnings Beat Despite Sales Decline

Published 02/18/2022, 10:46 AM
Updated 02/18/2022, 10:47 AM
© Reuters.

© Reuters.

By Sam Boughedda

Investing.com -- Quidel Corporation (NASDAQ:QDEL), the diagnostic healthcare products manufacturer, reported its fourth quarter numbers after the bell Thursday, beating analyst expectations on revenue and earnings.

The company's shares have rallied over 15% as a result.

Quidel posted earnings per share of $7.29 on revenue of $636.9 million. Analysts polled by Investing.com anticipated EPS of $5.61 on revenue of $540.9 million.

However, revenue fell from the $809.2 million reported in the fourth quarter of 2020.

Quidel said the decline was caused mainly by a $249 million revenue decline of the Sofia 2 Flu + SARS antigen FIA. In addition, there was a shift in the product mix for rapid immunoassay COVID-19 products from higher-priced Sofia products sold in the professional market to lower-priced QuickVue products sold in the retail, pharmacy, and employer testing markets.

Revenue from COVID-19 products rose to $511.8 million from $405.3 million in the fourth quarter of 2020, with Douglas Bryant, President and CEO of Quidel, saying demand for COVID-19 testing remains elevated.

The company launched the Savanna MDx instrumented system in select markets during the quarter. Commenting on the system, Bryant said it is a "key near-term opportunity" for the company.

"Based on customer reviews in Europe, we believe Savanna will be a major growth driver, both in the U.S. and globally, for years to come," he added.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.